---
title: Artificial intelligence-based biomarkers for treatment decisions in oncology
date: '2025-01-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39814650/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250116171035&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The development of new therapeutic strategies such as immune checkpoint
  inhibitors (ICIs) and targeted therapies has increased the complexity of the treatment
  landscape for solid tumors. At the current rate of annual FDA approvals, the potential
  treatment options could increase by tenfold over the next 5 years. The cost of personalized
  medicine technologies limits its accessibility, thus increasing socioeconomic disparities
  in the treated population. In this review we describe ...
disable_comments: true
---
The development of new therapeutic strategies such as immune checkpoint inhibitors (ICIs) and targeted therapies has increased the complexity of the treatment landscape for solid tumors. At the current rate of annual FDA approvals, the potential treatment options could increase by tenfold over the next 5 years. The cost of personalized medicine technologies limits its accessibility, thus increasing socioeconomic disparities in the treated population. In this review we describe ...